• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三种腺病毒E3蛋白协同作用,通过肿瘤坏死因子相关凋亡诱导配体受体-1和-2逃避凋亡。

Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2.

作者信息

Benedict C A, Norris P S, Prigozy T I, Bodmer J L, Mahr J A, Garnett C T, Martinon F, Tschopp J, Gooding L R, Ware C F

机构信息

Division of Molecular Immunology and the Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA.

出版信息

J Biol Chem. 2001 Feb 2;276(5):3270-8. doi: 10.1074/jbc.M008218200. Epub 2000 Oct 24.

DOI:10.1074/jbc.M008218200
PMID:11050095
Abstract

Adenovirus encodes multiple gene products that regulate proapoptotic cellular responses to viral infection mediated by both the innate and adaptive immune systems. The E3-10.4K and 14.5K gene products are known to modulate the death receptor Fas. In this study, we demonstrate that an additional viral E3 protein, 6.7K, functions in the specific modulation of the two death receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). The 6.7K protein is expressed on the cell surface and forms a complex with the 10.4K and 14.5K proteins, and this complex is sufficient to induce down-modulation of TRAIL receptor-1 and -2 from the cell surface and reverse the sensitivity of infected cells to TRAIL-mediated apoptosis. Down-modulation of TRAIL-R2 by the E3 complex is dependent on the cytoplasmic tail of the receptor, but the death domain alone is not sufficient. These results identify a mechanism for viral modulation of TRAIL receptor-mediated apoptosis and suggest the E3 protein complex has evolved to regulate the signaling of selected cytokine receptors.

摘要

腺病毒编码多种基因产物,这些产物可调节由先天免疫系统和适应性免疫系统介导的针对病毒感染的促凋亡细胞反应。已知E3 - 10.4K和14.5K基因产物可调节死亡受体Fas。在本研究中,我们证明腺病毒的另一种E3蛋白6.7K在特异性调节肿瘤坏死因子相关凋亡诱导配体(TRAIL)的两种死亡受体中发挥作用。6.7K蛋白在细胞表面表达,并与10.4K和14.5K蛋白形成复合物,该复合物足以诱导TRAIL受体-1和-2从细胞表面下调,并逆转受感染细胞对TRAIL介导的凋亡的敏感性。E3复合物对TRAIL - R2的下调依赖于受体的细胞质尾巴,但仅死亡结构域是不够的。这些结果确定了病毒调节TRAIL受体介导的凋亡的机制,并表明E3蛋白复合物已经进化以调节选定细胞因子受体的信号传导。

相似文献

1
Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2.三种腺病毒E3蛋白协同作用,通过肿瘤坏死因子相关凋亡诱导配体受体-1和-2逃避凋亡。
J Biol Chem. 2001 Feb 2;276(5):3270-8. doi: 10.1074/jbc.M008218200. Epub 2000 Oct 24.
2
Adenovirus RIDbeta subunit contains a tyrosine residue that is critical for RID-mediated receptor internalization and inhibition of Fas- and TRAIL-induced apoptosis.腺病毒RIDβ亚基含有一个酪氨酸残基,该残基对于RID介导的受体内化以及对Fas和TRAIL诱导的细胞凋亡的抑制作用至关重要。
J Virol. 2002 Nov;76(22):11329-42. doi: 10.1128/jvi.76.22.11329-11342.2002.
3
Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins.腺病毒蛋白对TRAIL诱导的细胞凋亡的抑制作用以及TRAIL受体1的强制内化
J Virol. 2001 Oct;75(19):8875-87. doi: 10.1128/JVI.75.19.8875-8887.2001.
4
Distinct domains in the adenovirus E3 RIDalpha protein are required for degradation of Fas and the epidermal growth factor receptor.腺病毒E3 RIDalpha蛋白中的不同结构域是Fas和表皮生长因子受体降解所必需的。
J Virol. 2003 Nov;77(21):11685-96. doi: 10.1128/jvi.77.21.11685-11696.2003.
5
The adenovirus E3/10.4K-14.5K proteins down-modulate the apoptosis receptor Fas/Apo-1 by inducing its internalization.腺病毒E3/10.4K-14.5K蛋白通过诱导凋亡受体Fas/Apo-1内化来下调其表达。
Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10072-7. doi: 10.1073/pnas.95.17.10072.
6
Two distinct transport motifs in the adenovirus E3/10.4-14.5 proteins act in concert to down-modulate apoptosis receptors and the epidermal growth factor receptor.腺病毒E3/10.4 - 14.5蛋白中的两个不同转运基序协同作用,下调凋亡受体和表皮生长因子受体。
J Biol Chem. 2003 Dec 19;278(51):51872-84. doi: 10.1074/jbc.M310038200. Epub 2003 Sep 23.
7
Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2.腺病毒E3-6.7K蛋白与E3-RID蛋白复合物共同作用,是TRAIL受体2内化和降解所必需的。
J Virol. 2004 Nov;78(22):12297-307. doi: 10.1128/JVI.78.22.12297-12307.2004.
8
The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis.腺病毒E3-10.4K/14.5K复合物介导细胞表面Fas(CD95)缺失及对Fas诱导的凋亡的抗性。
J Virol. 1997 Nov;71(11):8299-306. doi: 10.1128/JVI.71.11.8299-8306.1997.
9
Adenovirus E3-6.7K maintains calcium homeostasis and prevents apoptosis and arachidonic acid release.腺病毒E3-6.7K维持钙稳态,防止细胞凋亡和花生四烯酸释放。
J Virol. 2002 Feb;76(4):1578-87. doi: 10.1128/jvi.76.4.1578-1587.2002.
10
The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid.腺病毒E3-14.7K蛋白以及E3-10.4K/14.5K蛋白复合物可独立抑制肿瘤坏死因子(TNF)诱导的细胞凋亡,它们也能独立抑制TNF诱导的花生四烯酸释放。
J Virol. 1996 Aug;70(8):4904-13. doi: 10.1128/JVI.70.8.4904-4913.1996.

引用本文的文献

1
Inhibiting inflammation in adipocytes accelerates mammary tumor development in mice.抑制脂肪细胞中的炎症会加速小鼠乳腺肿瘤的发展。
J Clin Invest. 2025 Jun 17;135(16). doi: 10.1172/JCI187202.
2
An oncolytic adenovirus targeting SLAMF7 demonstrates anti-myeloma efficacy.一种靶向信号淋巴细胞激活分子家族成员7(SLAMF7)的溶瘤腺病毒显示出抗骨髓瘤疗效。
Leukemia. 2025 Apr 17. doi: 10.1038/s41375-025-02617-3.
3
Nonclinical characterization of ICVB-1042 as a selective oncolytic adenovirus for solid tumor treatment.ICVB-1042 作为一种选择性溶瘤腺病毒在实体瘤治疗中的非临床特征。
Commun Biol. 2024 Sep 13;7(1):1132. doi: 10.1038/s42003-024-06839-6.
4
Apoptosis and Phagocytosis as Antiviral Mechanisms.细胞凋亡和吞噬作用作为抗病毒机制。
Subcell Biochem. 2023;106:77-112. doi: 10.1007/978-3-031-40086-5_3.
5
Adenoviral Gene Therapy Vectors in Clinical Use-Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety.临床应用的腺病毒基因治疗载体 - 以复制型腺病毒形成及其对临床安全性的影响为例的基本方面。
Int J Mol Sci. 2023 Nov 20;24(22):16519. doi: 10.3390/ijms242216519.
6
A Renaissance for Oncolytic Adenoviruses?溶瘤腺病毒的复兴?
Viruses. 2023 Jan 26;15(2):358. doi: 10.3390/v15020358.
7
Development of Oncolytic Vectors Based on Human Adenovirus Type 6 for Cancer Treatment.基于人类腺病毒 6 型的溶瘤载体的开发用于癌症治疗。
Viruses. 2023 Jan 7;15(1):182. doi: 10.3390/v15010182.
8
Therapeutic Implementation of Oncolytic Viruses for Cancer Immunotherapy: Review of Challenges and Current Clinical Trials.溶瘤病毒在癌症免疫治疗中的治疗应用:挑战与当前临床试验综述
J Biomed Sci Res. 2022;4(2). doi: 10.36266/JBSR/164. Epub 2022 Oct 20.
9
A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study.重组人5型腺病毒(H101)联合化疗治疗晚期胃癌:一项回顾性队列研究
Front Oncol. 2021 Dec 9;11:752504. doi: 10.3389/fonc.2021.752504. eCollection 2021.
10
The evolution of regulated cell death pathways in animals and their evasion by pathogens.动物中受调控的细胞死亡途径的进化及其被病原体逃避的机制。
Physiol Rev. 2022 Jan 1;102(1):411-454. doi: 10.1152/physrev.00002.2021.